Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

[1]  G. Tollefson,et al.  Olanzapine in the treatment of schizoaffective disorder , 1998, Schizophrenia Research.

[2]  G. Tollefson,et al.  543 Olanzapine in the treatment of chizoaffective disorder , 1997, Schizophrenia Research.

[3]  T. Suppes,et al.  573 The atypical antipsychotic sertindole: A case series , 1997, Schizophrenia Research.

[4]  I. Rak,et al.  562 Overview of the efficacy of ‘seroquel’ (quetiapine) , 1997, Schizophrenia Research.

[5]  Michael F. Green,et al.  546 Risperidone vs. Haloperidol in treatment resistant schizophrenia , 1997, Schizophrenia Research.

[6]  R. Conley,et al.  536 Olanzapine VS. chlorpromazine in therapy-refractory schizophrenia , 1997, Schizophrenia Research.

[7]  A. Lahti,et al.  571 The action of sertindole on negative symptoms in schizophrenia , 1997, Schizophrenia Research.

[8]  W. Honer,et al.  518 A comparison of two atypical antipsychotics in treatment resistant schizoprehnia , 1997, Schizophrenia Research.

[9]  R. Kerwin,et al.  512 Preliminary report: Effecrs of clozapine and typical antipsychotics on striataland limbic dopamine D2/D2-like receptors in vivo by 123I epidepride spet , 1997, Schizophrenia Research.

[10]  G. Tollefson,et al.  539 Treatment failure with clozapine: Can olanzapine be the alternative therapy? , 1997, Schizophrenia Research.

[11]  R. Conley,et al.  535 Olanzapine response in therapy-refractory schizophrenia with substance abuse (SA) , 1997, Schizophrenia Research.

[12]  P. Wozniak,et al.  570 Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia , 1997, Schizophrenia Research.

[13]  A. Swann,et al.  574 A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life of sertindole in stable schizophrenic patients , 1997, Schizophrenia Research.

[14]  A. Wehnert,et al.  575 Comparing sertindole clinical data and patients across the oceans , 1997, Schizophrenia Research.

[15]  J. Bergman,et al.  Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs , 1997, Psychopharmacology.

[16]  F. Sams-Dodd.  Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. , 1997, Behavioural pharmacology.

[17]  C. Tamminga,et al.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.

[18]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[19]  G. Tollefson,et al.  Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. , 1997, American Journal of Psychiatry.

[20]  E. Richelson,et al.  Muscarinic m4 receptor activation by some atypical antipsychotic drugs. , 1997, European journal of pharmacology.

[21]  R. Murray,et al.  In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole – a 123I IBZM single photon emission tomography (SPET) study , 1997, Psychopharmacology.

[22]  K. Goa,et al.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. , 1997, Drugs.

[23]  P. Seeman,et al.  Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors , 1997, Neuropsychopharmacology.

[24]  Anthony A. Grace,et al.  Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs , 1997, Trends in Neurosciences.

[25]  K. Rasmussen,et al.  The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition , 1997, Neuroscience Letters.

[26]  G. Busatto,et al.  Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia , 1997, Journal of psychopharmacology.

[27]  F. Song,et al.  Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. , 1997, Journal of psychopharmacology.

[28]  C. Halldin,et al.  A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects , 1997, Neuropsychopharmacology.

[29]  H. Shannon,et al.  Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice , 1997, Psychopharmacology.

[30]  M. Piercey,et al.  Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. , 1996, The Journal of pharmacology and experimental therapeutics.

[31]  C R Ashby,et al.  Pharmacological actions of the atypical antipsychotic drug clozapine: A review , 1996, Synapse.

[32]  N. Swerdlow,et al.  Seroquel restores sensorimotor gating in phencyclidine-treated rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  Edward D. Levin,et al.  Cognitive Effects of Neonatal Hippocampal Lesions in a Rat Model of Schizophrenia , 1996, Neuropsychopharmacology.

[34]  S. Kasper,et al.  Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone , 1996, Psychiatry Research: Neuroimaging.

[35]  David J. King,et al.  Cognitive Functioning in Schizophrenia , 1996 .

[36]  I. Weiner,et al.  The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine , 1996, Biological Psychiatry.

[37]  N. Alpert,et al.  Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. , 1996, The Journal of pharmacology and experimental therapeutics.

[38]  J. Porter,et al.  Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine , 1996, Psychopharmacology.

[39]  A. Cools,et al.  Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex , 1996, Neuroscience.

[40]  M. Kleven,et al.  Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. , 1996, European journal of pharmacology.

[41]  Takeshi Inoue,et al.  Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear , 1996, Pharmacology Biochemistry and Behavior.

[42]  A. Cools,et al.  Activity of “Seroquel” (ICI 204,636) in Animal Models for Atypical Properties of Antipsychotics: A Comparison with Clozapine , 1996, Neuropsychopharmacology.

[43]  H. Fibiger,et al.  Effects of Chronic Haloperidol on Stress- and Stimulation-Induced Increases in Dopamine Release: Tests of the Depolarization Block Hypothesis , 1996, Neuropsychopharmacology.

[44]  J. Olney,et al.  Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity , 1996, Schizophrenia Research.

[45]  R. Kerwin,et al.  New Antipsychotics , 1996 .

[46]  H. Meltzer,et al.  PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  E. Eriksson,et al.  Inverse Agonism at Dopamine D2 Receptors , 1996, Neuropsychopharmacology.

[48]  L. Figur,et al.  Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. , 1996, Cerebral cortex.

[49]  P. Leeson,et al.  5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. , 1996, Journal of medicinal chemistry.

[50]  J. Kehne,et al.  Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. , 1996, The Journal of pharmacology and experimental therapeutics.

[51]  David L. Braff,et al.  Latent inhibition in schizophrenia , 1996, Schizophrenia Research.

[52]  G. Pearlson,et al.  Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach , 1996, Trends in Neurosciences.

[53]  G. Robertson,et al.  Contrasting Effects of Chronic Clozapine, SeroquelTM (ICI 204,636) and Haloperidol Administration on ΔFosB‐like Immunoreactivity in the Rodent Forebrain , 1996, The European journal of neuroscience.

[54]  C. Tamminga,et al.  The new generation of antipsychotic drugs , 1996, International clinical psychopharmacology.

[55]  S. Hirsch,et al.  ICI 204, 636: A New Atypical Antipsychotic Drug , 1996, British Journal of Psychiatry.

[56]  A. Fink-Jensen,et al.  Regional differences in the effect of haloperidol and atypical neuroleptics on interstitial levels of DOPAC in the rat forebrain: an in vivo microdialysis study , 1996, Journal of psychopharmacology.

[57]  C. Halldin,et al.  [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. , 1996, Life sciences.

[58]  E. Nestler,et al.  Chronic Alterations in Dopaminergic Neurotransmission Produce a Persistent Elevation of ΔFosB‐like Protein(s) in both the Rodent and Primate Striatum , 1996, The European journal of neuroscience.

[59]  O. Blin,et al.  Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. , 1996, Journal of clinical psychopharmacology.

[60]  K. Rasmussen,et al.  Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons , 1996, Neuropsychopharmacology.

[61]  H. Fibiger,et al.  Effects of Olanzapine on Regional C-Fos Expression in Rat Forebrain , 1996, Neuropsychopharmacology.

[62]  Charles M Beasley,et al.  Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.

[63]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[64]  A. Deutch,et al.  The effects of antipsychotic drugs on fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization , 1996, Neuroscience.

[65]  M. Millan,et al.  Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors , 1996, Neuropharmacology.

[66]  F. Sams-Dodd.  Phencyclidine‐induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia , 1996, Behavioural pharmacology.

[67]  J. Hitchcock,et al.  Effects of clozapine on latent inhibition in the rat , 1996, Behavioural pharmacology.

[68]  D. Sibley,et al.  Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.

[69]  P. Bonaventure,et al.  Antipsychotics and neuropeptides: The atypical profile of CI-943 and its relationship to neurotensin , 1995, Neuroscience & Biobehavioral Reviews.

[70]  G. Bondolfi,et al.  Treatment-resistant schizophrenia: clinical experience with new antipsychotics , 1995, European Neuropsychopharmacology.

[71]  D. Casey.  Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: ‘Seroquel’ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic , 1996 .

[72]  I. Jalenques.  Drug-Resistant Schizophrenia , 1996 .

[73]  D. Casey.  Side effect profiles of new antipsychotic agents. , 1996, The Journal of clinical psychiatry.

[74]  T. Goldberg,et al.  Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. , 1996, The Journal of clinical psychiatry.

[75]  P. Weiden,et al.  Atypical antipsychotic drugs and long-term outcome in schizophrenia. , 1996, The Journal of clinical psychiatry.

[76]  S. Ahlénius,et al.  Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. , 1995, European journal of pharmacology.

[77]  J. Kehne,et al.  Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist , 1995, Behavioural Brain Research.

[78]  C. Tamminga,et al.  D2-Family receptor distribution in human postmortem tissue: an autoradiographic study , 1995, Neuroreport.

[79]  G. Higgins,et al.  Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. , 1995, European journal of pharmacology.

[80]  Sipes Te,et al.  DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. , 1995 .

[81]  D. Hoffman,et al.  Effects of typical, atypical, and novel antipsychotic drugs on amphetamine‐induced place conditioning in rats , 1995 .

[82]  L. W. Cooke,et al.  Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. , 1995, The Journal of pharmacology and experimental therapeutics.

[83]  T. Sotnikova,et al.  Regulation of dopamine release and metabolism in rat striatum in vivo: Effects of dopamine receptor antagonists , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[84]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[85]  P. Voorn,et al.  Risperidone does not elevate neurotensin mRNA in rat nucleus accumbens and caudate-putamen. , 1995, Neuroreport.

[86]  P. Soubrié,et al.  Neuropharmacological profile of non‐peptide neurotensin antagonists , 1995, Fundamental & clinical pharmacology.

[87]  A. Wagstaff,et al.  Clozapine: A Review of its Pharmacological Properties and Therapeutic Use in Patients with Schizophrenia Who Are Unresponsive to or Intolerant of Classical Antipsychotic Agents , 1995 .

[88]  J. Peuskens,et al.  Risperidone in the treatment of negative symptoms of schizophrenia: a meta‐analysis , 1995, International clinical psychopharmacology.

[89]  C Dacquet,et al.  Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. , 1995, The Journal of pharmacology and experimental therapeutics.

[90]  Anne W. Schmidt,et al.  Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[91]  G. Sedvall,et al.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. , 1995, The American journal of psychiatry.

[92]  J. Arnt.  Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. , 1995, European journal of pharmacology.

[93]  J Gerlach,et al.  New antipsychotics: the present status , 1995, International clinical psychopharmacology.

[94]  Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat. , 1995, Life sciences.

[95]  T. Skarsfeldt.  Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. , 1995, European journal of pharmacology.

[96]  M. Didriksen.  Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. , 1995, European journal of pharmacology.

[97]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[98]  Alan A. Wilson,et al.  The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. , 1995, Life sciences.

[99]  A. Fink-Jensen,et al.  The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of α1-adrenergic or 5HTZ receptor blockade to haloperidol , 1995, Neuroscience Letters.

[100]  M. Millan,et al.  Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. , 1995, European journal of pharmacology.

[101]  T Suhara,et al.  Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[102]  R. Corbett.  Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue , 1995, Pharmacology Biochemistry and Behavior.

[103]  J. Peuskens.  Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol , 1995, British Journal of Psychiatry.

[104]  K. Rasmussen,et al.  Olanzapine, a novel atypical antipsychotic, has electrophysiological effects on A9 and A10 dopamine cells similar to clozapine , 1995, Schizophrenia Research.

[105]  H. Fibiger,et al.  Receptor mechanisms mediating clozapine-inducedc-fos expression in the forebrain , 1995, Neuroscience.

[106]  J. L. Howard,et al.  Olanzapine moderately increases conflict responding but does not produce a benzodiazepine‐like cue in rat , 1995 .

[107]  C. Halldin,et al.  D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.

[108]  G. Perrault,et al.  Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[109]  C. Halldin,et al.  Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. , 1995, Journal of clinical psychopharmacology.

[110]  J. Korf,et al.  Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. , 1995, European journal of pharmacology.

[111]  B. Costall,et al.  Sertindole: A limbic selective neuroleptic with potent anxiolytic effects , 1995 .

[112]  N. Yamaguchi,et al.  Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. , 1995 .

[113]  R. Wise,et al.  D2-family receptors in schizophrenia: Distribution and implications for treatment , 1995 .

[114]  R. Buchanan.  Clozapine: efficacy and safety. , 1995, Schizophrenia bulletin.

[115]  Haloperidol-induced decrements in force and duration of rats' tongue movements during licking are attenuated by concomitant anticholinergic treatment , 1994, Pharmacology Biochemistry and Behavior.

[116]  J. Wiley.  Clozapine's effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response , 1994, Pharmacology Biochemistry and Behavior.

[117]  A. Fink-Jensen,et al.  Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain , 1994, Neuroscience Letters.

[118]  S. Zorn,et al.  Clozapine is a potent and selective muscarinic M4 receptor agonist. , 1994, European journal of pharmacology.

[119]  E. sanders-Bush,et al.  Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. , 1994, Molecular pharmacology.

[120]  N. Swerdlow,et al.  Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. , 1994, The Journal of pharmacology and experimental therapeutics.

[121]  H. Fibiger,et al.  Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. , 1994, The Journal of pharmacology and experimental therapeutics.

[122]  D. Dorsa,et al.  Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. , 1994, The Journal of pharmacology and experimental therapeutics.

[123]  E. Stein,et al.  Behavioral and pharmacological modulation of ventral tegmental dendritic dopamine release , 1994, Brain Research.

[124]  A. Cools,et al.  Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. , 1994, European journal of pharmacology.

[125]  K. Fuxe,et al.  The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors , 1994, Neuroscience.

[126]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[127]  D. Jackson,et al.  Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats , 1994, Pharmacology Biochemistry and Behavior.

[128]  I. Weiner,et al.  The effects of the new antipsychotic, sertindole, on latent inhibition in rats , 1994, Behavioural pharmacology.

[129]  N. Moore,et al.  Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule , 1994, Behavioural pharmacology.

[130]  B. Costall,et al.  Effect of sertindole on raised mesolimbic dopaminergic activity in the rat , 1994 .

[131]  H. Meltzer,et al.  Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. , 1994, The Journal of pharmacology and experimental therapeutics.

[132]  M. Geyer,et al.  Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats , 1994, Neuropharmacology.

[133]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[134]  N. Yamaguchi,et al.  In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol , 1994, Pharmacology Biochemistry and Behavior.

[135]  N. Swerdlow,et al.  Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. , 1994, Archives of general psychiatry.

[136]  M. Didriksen,et al.  The effects of amphetamine, phencyclidine, dopaminergic antagonists and atypical neuroleptics on schedule‐induced polydipsia (SIP) are distinguishable , 1994, Behavioural pharmacology.

[137]  U. Ungerstedt,et al.  Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release , 1994, Brain Research.

[138]  R. Roth,et al.  Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment , 1994, Neuroscience Letters.

[139]  D. M. Jackson,et al.  Dopamine receptors: molecular biology, biochemistry and behavioural aspects. , 1994, Pharmacology & therapeutics.

[140]  Trevor W. Robbins,et al.  Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia , 1993, Biological Psychiatry.

[141]  H. Meltzer,et al.  Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. , 1993, The Journal of pharmacology and experimental therapeutics.

[142]  J. Kehne,et al.  Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. , 1993, The Journal of pharmacology and experimental therapeutics.

[143]  P. Seeman,et al.  Dopamine receptor pharmacology. , 1994, Trends in pharmacological sciences.

[144]  F. Gonon,et al.  Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo , 1993, Neuroscience Letters.

[145]  B. Bunney,et al.  Depolarization inactivation of dopamine neurons: Terminal release characteristics , 1993, Synapse.

[146]  D. Evans,et al.  Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. , 1993, European journal of pharmacology.

[147]  J. Wiley,et al.  Effects of four antipsychotics on punished responding in rats , 1993, Pharmacology Biochemistry and Behavior.

[148]  D. Jackson,et al.  Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.

[149]  H. Hartman,et al.  Effects of atypical antipsychotic agents on social behavior in rodents , 1993, Pharmacology Biochemistry and Behavior.

[150]  I. Kusumi,et al.  Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. , 1993, The Journal of pharmacology and experimental therapeutics.

[151]  D. Dorsa,et al.  Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[152]  N. Swerdlow,et al.  Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia , 1993, Pharmacology Biochemistry and Behavior.

[153]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[154]  T. Svensson,et al.  Effects of amperozide on psychostimulant-induced hyperlocomotion and dopamine release in the nucleus accumbens , 1993, Pharmacology Biochemistry and Behavior.

[155]  B. Ellenbroek,et al.  Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. , 1993, Pharmacology & therapeutics.

[156]  Richard Muscat,et al.  Chronic mild stress-induced anhedonia: A realistic animal model of depression , 1992, Neuroscience & Biobehavioral Reviews.

[157]  G. Rigdon,et al.  5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. , 1992, The Journal of pharmacology and experimental therapeutics.

[158]  J. Woods,et al.  The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[159]  D. Dorsa,et al.  Expression of the Proneurotensin Gene in the Rat Brain and Its Regulation by Antipsychotic Drugs a , 1992, Annals of the New York Academy of Sciences.

[160]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[161]  A. Deutch,et al.  Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action , 1992, Molecular and Cellular Neuroscience.

[162]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[163]  H. Meltzer,et al.  Amperozide, a Novel Antipsychotic Drug, Inhibits the Ability of d‐Amphetamine to Increase Dopamine Release In Vivo in Rat Striatum and Nucleus Accumbens , 1992, Journal of neurochemistry.

[164]  Coward Dm,et al.  General pharmacology of clozapine. , 1992 .

[165]  M. Papp,et al.  Antidepressant-like effects of dopamine agonists in an animal model of depression , 1992, Biological Psychiatry.

[166]  Eric R. Marsh,et al.  Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine? , 1992, British Journal of Psychiatry.

[167]  V. Chretensena.  LEARNED HELPLESSNESS: AN ANIMAL MODEL OF DEPRESSION , 1992 .

[168]  A. Cools,et al.  ROLE OF OLFACTORY TUBERCLE AND NUCLEUS ACCUMBENS IN THE EFFECTS OF CLASSICAL AND ATYPICAL NEUROLEPTICS , 1992 .

[169]  J. Arnt.  Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats , 1992, Behavioural pharmacology.

[170]  B. Smith,et al.  Remoxipride, a specific D2 dopamine antagonist: An examination of its self-administration liability and its effects on d-amphetamine self-administration , 1992, Pharmacology Biochemistry and Behavior.

[171]  H. Fibiger,et al.  Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine , 1992, Neuroscience.

[172]  E. Ben-Artzi,et al.  Effects of antipsychotic drugs on memory functions of schizophrenic patients , 1992, Acta psychiatrica Scandinavica.

[173]  T. Skarsfeldt.  Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: Acute and repeated treatment , 1992, Synapse.

[174]  A. Megens,et al.  Antipsychotic profile and side‐effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats , 1992 .

[175]  A. Deutch.  The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. , 1992, Journal of neural transmission. Supplementum.

[176]  H. Meltzer,et al.  Effects of antipsychotic drugs on serotonin receptors. , 1991, Pharmacological reviews.

[177]  R. Roth,et al.  Effects of haloperidol administration on in vivo extracellular dopamine in striatum and prefrontal cortex after partial dopamine lesions , 1991, Brain Research.

[178]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[179]  I. Weiner,et al.  The latent inhibition model of schizophrenic attention disorder Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli , 1991, Biological Psychiatry.

[180]  R. Baldessarini,et al.  Clozapine. A novel antipsychotic agent. , 1991, The New England journal of medicine.

[181]  P. Willner,et al.  Changes in mesolimbic dopamine may explain stress-induced anhedonia , 1991, Psychobiology.

[182]  J. Rawlins,et al.  The neuropsychology of schizophrenia , 1991, Behavioral and Brain Sciences.

[183]  B. Bunney,et al.  Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia , 1991, Schizophrenia Research.

[184]  R. Skelton,et al.  Diazepam impairs acquisition but not performance in the morris water maze , 1991, Pharmacology Biochemistry and Behavior.

[185]  C. Nemeroff,et al.  Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs , 1991, Regulatory Peptides.

[186]  I. Weiner,et al.  An Animal Model of Attention Deficit , 1991 .

[187]  G. Rigdon,et al.  Prepulse inhibition as a screening test for potential antipsychotics , 1991 .

[188]  C. Sánchez,et al.  Neurochemical and in vivo pharmacological profile of sertindole, a limbic‐selective neuroleptic compound , 1991 .

[189]  B. Ellenbroek.  The Ethological Analysis of Monkeys in a Social Setting as an Animal Model for Schizophrenia , 1991 .

[190]  J. Brioni,et al.  Diazepam impairs place learning in the Morris water maze. , 1991, Behavioral and neural biology.

[191]  C. Nemeroff,et al.  The electrophysiological actions of neurotensin in the central nervous system. , 1991, Life sciences.

[192]  M. Dragunow,et al.  D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons , 1990, Neuroscience.

[193]  L. Pozzi,et al.  Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats , 1990, British journal of pharmacology.

[194]  G. Ellison,et al.  Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. , 1990, European journal of pharmacology.

[195]  R. Beninger,et al.  Do neuroleptics impair learning in schizophrenic patients? , 1990, Schizophrenia Research.

[196]  B. Bunney,et al.  Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study , 1990, Journal of neurochemistry.

[197]  T. Lewander,et al.  Clinical profile of remoxipride ‐ a combined analysis of a comparative double‐blind multicentre trial programme , 1990, Acta psychiatrica Scandinavica. Supplementum.

[198]  Jeannette C. Miller.  Induction of c‐fos mRNA Expression in Rat Striatum by Neuroleptic Drugs , 1990, Journal of neurochemistry.

[199]  E. Richelson,et al.  Cardiovascular effects of neurotensin and some analogues on rats. , 1990, European journal of pharmacology.

[200]  T. Meert,et al.  Pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat , 1990 .

[201]  B. Gustafsson,et al.  Amperozide--a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. , 1990, Pharmacology & toxicology.

[202]  A. Cools,et al.  Animal models with construct validity for schizophrenia. , 1990, Behavioural pharmacology.

[203]  B. Gustafsson,et al.  Amperozide and emotional behaviour. , 1990, Pharmacology & toxicology.

[204]  T. Svensson,et al.  Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. , 1990, Pharmacology & toxicology.

[205]  S. Potkin,et al.  Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain , 1990, Synapse.

[206]  G. Marek,et al.  Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. , 1989, The Journal of pharmacology and experimental therapeutics.

[207]  R. Hemmingsen,et al.  Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. , 1989, European journal of pharmacology.

[208]  T. Svensson,et al.  Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. , 1989, Acta physiologica Scandinavica.

[209]  J. Hollerman,et al.  Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions , 1989, Neuroscience Letters.

[210]  K. Bogeso,et al.  In vivo pharmacology of irindalone, a 5‐HT2 receptor antagonist with predominant peripheral effects , 1989 .

[211]  S. Dworkin,et al.  6‐Hydroxydopamine lesions of the nucleus accumbens attenuate the discriminative stimulus effects of d‐amphetamine , 1989 .

[212]  A. Imperato,et al.  The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. , 1989, Psychopharmacology bulletin.

[213]  Serge Bischoff,et al.  Blockade of hippocampal dopamine (da) receptors: A tool for antipsychotics with low extrapyramidal side effects , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[214]  Daniel R. Weinberger,et al.  Schizophrenia and the frontal lobe , 1988, Trends in Neurosciences.

[215]  T. Svensson,et al.  The excitatory amino acid antagonist kynurenate induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. , 1988, Acta physiologica Scandinavica.

[216]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[217]  T. Svensson,et al.  Firing patterns of midbrain dopamine neurons: differences between A9 and A10 cells. , 1988, Acta physiologica Scandinavica.

[218]  E. Levin.  Psychopharmacological effects in the radial-arm maze , 1988, Neuroscience & Biobehavioral Reviews.

[219]  C. Kilts,et al.  Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. , 1988, Biochemical pharmacology.

[220]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[221]  B. Costall,et al.  Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain , 1987, British journal of pharmacology.

[222]  J. Hyttel,et al.  Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. , 2009, Acta pharmacologica et toxicologica.

[223]  A. Grace,et al.  Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. , 1986, The Journal of pharmacology and experimental therapeutics.

[224]  J. Scheel-Krüger,et al.  Cueing effects of amphetamine and LSD: elicitation by direct microinjection of the drugs into the nucleus accumbens. , 1986, European journal of pharmacology.

[225]  B. Westerink,et al.  Effect of Various Centrally Acting Drugs on the Efflux of Dopamine Metabolites from the Rat Brain , 1986, Journal of neurochemistry.

[226]  H. Aihara,et al.  Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. , 1986, Japanese journal of pharmacology.

[227]  G. Di Chiara,et al.  Rapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats. , 1985, Journal of Pharmacology and Experimental Therapeutics.

[228]  B. Bunney,et al.  Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[229]  E. B. Nielsen,et al.  Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. , 1985, European journal of pharmacology.

[230]  G. Di Chiara,et al.  Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[231]  C. Frith.  Schizophrenia, memory, and anticholinergic drugs. , 1984, Journal of abnormal psychology.

[232]  H. Hall,et al.  Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. , 1984, European journal of pharmacology.

[233]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[234]  F. Borsini,et al.  Effect of repeated treatment with desipramine in the behavioral "despair" test in rats: antagonism by "atypical" but not "classical" neuroleptics or antiadrenergic drugs. , 1984, Life sciences.

[235]  T. Hökfelt,et al.  Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons , 1984, The Journal of comparative neurology.

[236]  F. J. White,et al.  Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. , 1983, Science.

[237]  B. Bunney,et al.  Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[238]  J. R. Rush,et al.  Spatial working memory in rats: Effects of monoaminergic antagonists , 1983, Pharmacology Biochemistry and Behavior.

[239]  J. Arnt,et al.  Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. , 2009, Acta pharmacologica et toxicologica.

[240]  J. Hyttel,et al.  Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential. , 1981, Neuropharmacology.

[241]  J. Arnt,et al.  Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. , 1981, European journal of pharmacology.

[242]  C. Nemeroff.  Neurotensin: perchance an endogenous neuroleptic? , 1980, Biological psychiatry.

[243]  S. Iversen,et al.  Behavioral consequences of long-term treatment with neuroleptic drugs. , 1980, Advances in biochemical psychopharmacology.

[244]  A. Grace,et al.  Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. , 1978, Life sciences.

[245]  Aghajanian Gk.  Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. , 1978 .

[246]  J. Scheel-Krüger,et al.  Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drugs: a complex GABA-dopamine interaction. , 1978, Life sciences.

[247]  G. Uhl,et al.  Neurotensin: immunohistochemical localization in rat central nervous system. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[248]  R. Roth,et al.  Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. , 1973, The Journal of pharmacology and experimental therapeutics.

[249]  K. Fuxe,et al.  The effect of (+)‐amphetamine on various central and peripheral catecholamine‐containing neurones , 1966, The Journal of pharmacy and pharmacology.